NewLink Genetics Plunges After Competitor IDO Drug Fails In Trial
Shares of NewLink Genetics (NLNK), a clinical-stage company focused on developing and commercializing immunotherapeutic products for the treatment of cancer, plunged in pre-market trading after a competitor exploring the same areas of cancer treatment reported a clinical trial that did not succeed in achieving its goal. Incyte/Merck Combo Misses Mark Incyte (INCY) and partner Merck…